We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes.
- Authors
Hsu, Nin-Chieh; Tsai, Hung-Bin; Hsu, Chia-Hao
- Abstract
Comment & Response B To the Editor b We have several concerns about the recent randomized clinical trial[1] that reported that children and adolescents aged 7 to 17 years with newly diagnosed type 1 diabetes who were treated with oral verapamil starting within 31 days after diagnosis had preserved stimulated C-peptide secretion at 52 weeks compared with placebo. Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. First, the authors stated that few verapamil-related adverse events were observed in this study, and that none of them were serious.[1] However, of the 47 participants treated with verapamil, 4 (8.5%) had potentially life-threatening adverse events (3 had first- or second-degree heart block and 1 had hypotension).
- Subjects
TYPE 1 diabetes; PANCREATIC beta cells; BETA functions; CELL physiology; VERAPAMIL
- Publication
JAMA: Journal of the American Medical Association, 2023, Vol 330, Issue 4, p380
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2023.9110